VIGL - Vigil Neuroscience, Inc.
IEX Last Trade
1.65
-0.055 -3.333%
Share volume: 6,505
Last Updated: Thu 26 Dec 2024 08:29:40 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.70
-0.06
-3.23%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.16%
1 Month
-25.91%
3 Months
-50.15%
6 Months
-56.88%
1 Year
-55.34%
2 Year
-85.49%
Key data
Stock price
$1.65
DAY RANGE
$1.58 - $1.74
52 WEEK RANGE
$1.72 - $6.03
52 WEEK CHANGE
-$55.83
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Ivana Magovcevic-Liebisch
Region: US
Website: vigilneuro.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vigilneuro.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vigil Neuroscience, Inc. engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) The company also develops a small molecule TREM2 agonist suitable for oral delivery.
Recent news